Allogene Therapeutics (ALLO) Research & Development: 2019-2025
Historic Research & Development for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $31.2 million.
- Allogene Therapeutics' Research & Development fell 30.30% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.5 million, marking a year-over-year decrease of 17.57%. This contributed to the annual value of $192.3 million for FY2024, which is 20.84% down from last year.
- Allogene Therapeutics' Research & Development amounted to $31.2 million in Q3 2025, which was down 22.39% from $40.2 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Research & Development peaked at $80.2 million during Q1 2023, and registered a low of $31.2 million during Q3 2025.
- Its 3-year average for Research & Development is $50.6 million, with a median of $50.2 million in 2025.
- Per our database at Business Quant, Allogene Therapeutics' Research & Development skyrocketed by 39.71% in 2022 and then tumbled by 34.87% in 2024.
- Allogene Therapeutics' Research & Development (Quarterly) stood at $54.0 million in 2021, then soared by 39.71% to $75.4 million in 2022, then dropped by 27.52% to $54.7 million in 2023, then dropped by 17.73% to $45.0 million in 2024, then tumbled by 30.30% to $31.2 million in 2025.
- Its Research & Development stands at $31.2 million for Q3 2025, versus $40.2 million for Q2 2025 and $50.2 million for Q1 2025.